# C007-C013 — Conversation Record

**Status:** In progress. C007-C010 have been discussed; C011-C013 remain to be added.

**Saved:** 2026-10-22T00:28:08Z

This file preserves the user requests, assistant answers, and visible progress updates from the current conversation through the export request and its acknowledgement. Message text, English source quotations, Chinese explanations, and local links are preserved. Raw tool calls/outputs and internal reasoning are excluded. The initial user-supplied workspace context is preserved in the appendix. The unfinished sections below are editing placeholders, not completed reviews.

## Conversation

### 1. User

Read the local files and then tell me what happened to C007 in CN. Make sure that 1. you need to read and explore independently and compare with existing records. 2. include key sentences from the source, and point out source locations. Key sentences should be in ENG, and you should provide CN translations (stat terminologies should not be translated). 3. assess down stream impact if the Review domain is statistical_results. 4. provide detailed reasoning regarding yout independent explorations in CN. 5. Not allowed to create any files in local except from the specifically provided subfolder ./review_records/re_explorations/*

---

### 2. Assistant — progress update

我会先独立核查 C007 涉及的原始材料，再与现有审查记录对照，并用中文说明其处理经过、依据及可能的下游影响。所有本地写入都将限于你指定的 `review_records/re_explorations/` 目录。

---

### 3. Assistant — progress update

现有目录将 C007 指向 SAP 与论文之间的 primary analysis 差异。我会核查计划中是否明确要求调整烟草使用形式，以及论文和补充结果是否报告了对应分析。接下来的页面渲染使用 CPU；如你提出要求，可再使用经你同意的 GPU OCR。

---

### 4. Assistant — progress update

原文已确认：SAP 的 “Sensitivity Analyses → Adjusted Analyses” 明确列出 tobacco use form，而论文 Methods、Table 2 及补充表注释列出的五项 covariates 均未包含它。C007 在现有记录中的 Review domain 是 `protocol_report`。这里需要保留一个关键区别：未报告对应分析，并不能证明实际拟合时没有纳入该变量。

---

### 5. Assistant — progress update

与现有 screening、recheck、audit 和最终报告对照后，C007 的记录一致：两个 findings 合并为一个 candidate，保留 `reproduced` 和 `CONFIRMED`，仍为 `Pending Human Adjudication`。我也核实了一个表述边界：该项调整要求位于 SAP 的 sensitivity analyses 下，更准确地说，是针对 primary outcome 的计划调整分析缺少明确对应结果，不能据此说整个 primary analysis 未被报告。

---

### 6. Assistant — answer

**C007 被保留在最终报告中，仍为 `Pending Human Adjudication`。我独立复查后重现了其核心 discrepancy：SAP 明确列出 tobacco-use-form adjustment，但论文反复列出的 covariates 中没有该项，也未找到明确对应的计划分析结果。其 Review domain 是 `protocol_report`，relationship type 是 `P_R`。**

需要把结论限定清楚：现有证据支持“计划与报告之间缺少明确对应”，不能证明实际拟合时没有纳入该变量，也不能证明它改变了研究结果。

**一、原始材料究竟说了什么**

以下页码均为 PDF 页码，并同时注明文内页码或位置；统计术语在中文译文中保留英文。

**① SAP 明确列出烟草使用形式。**

位置：[Supplement 1，PDF p.92](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=92>)，SAP 文内 p.15，§35 “Sensitivity Analyses”／§36 “Adjusted Analyses”，行 2920–2923：

> “The fully adjusted analysis models will be controlled for by adjusting for sociodemographic variables alongside tobacco use form and other baseline characteristics (such as education level and smoking duration)..”

中文：fully adjusted analysis models 将对 sociodemographic variables 进行 adjustment，同时纳入烟草使用形式及其他 baseline characteristics，例如受教育程度和吸烟年限。

这里的 **“alongside tobacco use form” 是明确列出的分析要素**，并非根据临床常识推测应该加入的 covariate。

**② 论文明确列出的 covariates 是另外五项，并说明为 post hoc selection。**

位置：[正文，PDF p.3](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=3>)，文内 p.338，右栏 “Statistical Analysis”：

> “A mixed-effects model was used to assess the effect of mHealth on abstinence outcomes, incorporating fixed effects for the intervention and relevant covariates selected post hoc (age, sex, education, occupation, and smoking duration) and random effects for clusters.”

中文：采用 mixed-effects model 评估 mHealth 对戒烟 outcomes 的作用；fixed effects 包含干预及通过 post hoc selection 选取的相关 covariates——年龄、性别、教育、职业和吸烟年限，并为 clusters 设置 random effects。

同页还明确写道：

> “We adjusted for relevant sociodemographic covariates (selected post hoc) in the primary analysis.”

中文：在 primary analysis 中，对相关 sociodemographic covariates 进行了 adjustment，这些 covariates 通过 post hoc selection 选取。

**③ 这五项 covariates 与具体的 primary outcome 结果相连。**

位置：[正文，PDF p.4](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=4>)，文内 p.339，右栏 “Primary Outcome”：

> “The association persisted after adjustments for baseline covariates selected post hoc (age, sex, education, occupation, and smoking duration) (adjusted risk ratio, 3.2 [95% CI, 2.2-5.2]).”

中文：对通过 post hoc selection 选取的 baseline covariates——年龄、性别、教育、职业和吸烟年限——进行 adjustment 后，该 association 仍存在，adjusted risk ratio 为 3.2［95% CI，2.2–5.2］。

同样的五项还出现在：

- [正文 PDF p.6，Table 2，footnote a](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=6>)。
- [Supplement 2，PDF p.14，eTable 9，footnote e](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp2_prod_1768590553.09463.pdf#page=14>)。其上一页的 death-excluded analysis 报告 adjusted RR 3.1［95% CI，1.9–6.5］。

因此，这并非单一段落漏写一个词的孤立观察；多个报告位置给出了相同列表，但都没有明确对应 tobacco-use form。

**二、C007 在既有审查记录中经历了什么**

| 阶段 | 记录中的处理 |
|---|---|
| 初始发现 | Cross-source checker 的 `F-XS-003` 与 statistical pass 1 的 `F-ST1-005` 分别提出同一问题。 |
| Inclusion screening | 两条 findings 均为 `INCLUDE / MEETS_THRESHOLD`，合并对应一个 candidate：C007。 |
| Evidence recheck | 确认源文与比较位置，记录为 `reproduced`；同时明确，没有推断实际代码排除了该变量。 |
| Statistical pass 2 | 在 `S090` 中保留 C007，没有再生成重复 finding。 |
| Quality audit 与最终报告 | Inclusion audit 为 `CONFIRMED`；分类保持 `protocol_report / P_R`；继续等待人工 adjudication。 |

对应记录可查：[screening](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/screening/inclusion_screen.md:19>)、[evidence recheck](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md:203>)、[statistical pass 2](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/checkers/statistical_pass_2.md:324>)、[最终报告 C007](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/final_report_1_6_2.md:512>)。

其中，`CONFIRMED` 指的是 **inclusion audit 的记录**，不是人工 adjudication 已完成。

**三、我的独立复查如何限定这个问题**

我先用 C007 的编号定位材料，直接核查源文并比较 covariate lists，再对照详细审查记录；另有一名独立 reviewer 仅检查原始材料，没有读取既有 candidate 结论。

独立探索得到以下几点：

1. **应准确区分 primary analysis 与针对 primary outcome 的 sensitivity analysis。**  
   SAP 的 §30 “Primary outcome Analysis” 位于 [PDF p.91](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=91>)，没有明确列出 tobacco-use form；明确要求该项 adjustment 的文字在下一页的 “Sensitivity Analyses → Adjusted Analyses” 下。因此，既有记录中的“planned fully adjusted primary model”需要结合这一层级理解。更精确的表述是：**SAP 所列、涉及 primary outcome 的 fully adjusted／sensitivity analysis，未找到明确对应的报告结果。**不能扩大成整个 primary analysis 未报告。

2. **smoking duration 不能自动视为 tobacco-use form 的对应项。**  
   [Table 1，正文 PDF p.5](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=5>)分别列出 smoking type、concurrent smokeless tobacco use 和 smoking duration。材料没有提供将这些不同字段映射为同一个 model term 的说明。不过，SAP 也没有清楚给出 tobacco-use form 的具体 coding，不能自行指定它究竟代表哪些 indicator variables。

3. **论文已经披露 post hoc selection，但这不能说明计划中的分析结果在哪里。**  
   所以，不能说作者没有披露 covariate selection 的性质；待解释的是：报告的五项 covariates 与 SAP 的要求如何对应，是否另有计划模型及结果。

4. **已核查的 change statement 没有提供对应说明。**  
   [Supplement 1，PDF p.77](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=77>)列出的 v4–v6 变更没有提到删除 tobacco-use form 或更换 adjustment set。这只说明该份变更说明没有解释它，不能证明不存在其他 amendment。另外，本次也没有建立 SAP 在接触 outcome data 之前锁定的时间证据；“供应的 SAP 有此规定”比“已独立证明其为 pre-data prespecification”更稳妥。

5. **分类应保留为 `protocol_report`。**  
   比较双方是 PLAN 的分析要求与 REPORT 的分析描述；正文和结果补充材料之间的列表彼此一致。因此支持 `P_R`，没有由此形成独立的 `S_C` 或 `S_W` conflict。

**四、可能的 downstream impact**

C007 的实际 Review domain **不是 `statistical_results`**，所以你提出的该类别条件并未触发。不过，它与结果的后续提取有关：

- **能明确指出的潜在影响是分析来源和 adjustment metadata。** Data extractor 可能把 adjusted RR 3.2，或 death-excluded adjusted RR 3.1，标记为已执行 SAP 所列 tobacco-form adjustment；目前材料不足以支持这一标记。
- **数值影响无法量化。** 缺少相应 model formula、fitting output，以及可匹配的含／不含 tobacco-use-form 模型结果，不能计算该项对 RR、95% CI 或后续 meta-analysis weight 的影响。
- **RR 3.0 与 adjusted RR 3.2 的差异不能归因于 tobacco-use form。** 这两个数字并没有构成仅改变该一项 covariate 的模型比较。
- **不能据此断言 statistical significance、效应方向或临床结论改变。** 本次重现的是计划与报告描述之间的 discrepancy，没有重新拟合模型，也没有改变原始 counts 或 denominators。

本次新增文件全部位于你允许的目录，原始材料与既有审查记录未修改；三个源 PDF 的 SHA-256 检查均通过。完整复查依据保存在[独立源文核查](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c007_20261021/independent_source_check.md>)及[既有记录对照](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c007_20261021/coordinator_comparison.md>)中。

---

### 7. User

continue on C008

---

### 8. Assistant — progress update

我会按同样要求复查 C008：先独立核查原始材料，再对照既有记录，用中文说明依据、处理经过及适用的下游影响；新增文件仍仅写入 `review_records/re_explorations/`。

---

### 9. Assistant — progress update

C008 涉及 CO<6 ppm 的 sensitivity analysis 为什么出现在 “Primary outcome(s)” 表格区块中。我会核查表格标题与 Methods 能否共同解释这一安排，以及它是否足以说明 outcome status 发生变化。页面渲染继续使用 CPU；如你提出要求，可使用经你同意的 GPU OCR。

---

### 10. Assistant — progress update

独立核查确认，Methods 明确将 CO<6 ppm 称为 post hoc sensitivity analysis，eTable 9 的完整标题也说明它是 sensitivity analysis。这支持将 “Primary outcomes” 理解为按 outcome 分组，而不一定表示其正式地位发生变化。另外，本次直接读取 Table 2 的 CO<6 PP 行得到 **38/318、11.9%**；既有 recheck 和最终报告写的是 **39/318**，我会将这项转录差异单独说明。

---

### 11. Assistant — answer

**C008 的关键经过是：最初被纳入，随后 quality audit 质疑其纳入前提，最终保留编号并标记 `QUESTIONED`，仍为 `Pending Human Adjudication`。**

我的独立复查与这项 audit concern 一致：**CO<6 ppm 的结果确实放在 “Primary outcome(s)” 表格区块下，但原文明确将其称为 post hoc sensitivity analysis，尚不能据此认定 primary outcome status 发生改变。**另外，我发现既有审查记录的一项数字转录与原文不一致：Table 2 的相关单元格是 **38/318**，并非记录中的 **39/318**。

**一、原始材料的关键句及位置**

**① SAP 的 primary endpoint 使用 CO<10 ppm。**

位置：[Supplement 1，PDF p.84](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=84>)，SAP 文内 p.7，§10 “Primary Outcome(s)”，行 2656–2660：

> “The primary endpoint will be biochemically verified continuous abstinence at 6 months post randomisation.”

中文：primary endpoint 为 randomisation 后6个月经生化核实的持续戒烟。

随后明确规定：

> “Abstinence is defined as self-report of not having used more than 5 cigarettes, bidis, water pipe sessions since the quit date, verified biochemically by a breath carbon monoxide (CO) reading of less than 10 ppm at month 6.”

中文：戒烟定义为自报自戒烟日起使用香烟、比迪烟或水烟的次数不超过5次，并通过第6个月呼出气 CO 读数低于10 ppm 进行生化核实。

**② 正文明确将 CO<6 ppm 定义为 post hoc sensitivity analysis。**

位置：[正文，PDF p.3](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=3>)，文内 p.338，右栏 “Statistical Analysis”：

> “A post hoc sensitivity analysis using a carbon monoxide cutoff of less than 6 ppm was performed for the primary outcome.”

中文：针对 primary outcome，进行了采用 CO cutoff 低于6 ppm 的 post hoc sensitivity analysis。

这句话区分了 **“for the primary outcome”** 与 **“被指定为另一个 primary outcome”**。前者说明分析对象，不能自动推出后者。

**③ Results 也区分了 post hoc analysis 与 primary analysis。**

位置：[正文 PDF p.4](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=4>)，文内 p.339，“Primary Outcome”段，句子延续至 PDF p.5：

> “The post hoc analysis using a CO cutoff of less than 6 ppm was also consistent with the primary analysis (RR, 3.7 [95% CI, 2.4-5.8]), confirming the robustness of the intervention effect.”

中文：采用 CO cutoff 低于6 ppm 的 post hoc analysis 也与 primary analysis 一致，RR 为3.7［95% CI，2.4–5.8］，支持 intervention effect 的 robustness。

**④ 补充表的完整标题直接说明其性质。**

位置：[Supplement 2，PDF p.13，eTable 9](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp2_prod_1768590553.09463.pdf#page=13>)：

> “Post-hoc sensitivity analysis (intention to treat) after excluding deaths”

中文：排除死亡参与者后的 post-hoc sensitivity analysis，采用 intention to treat。

同一张表下方确实有 “Primary outcomes” 区块，并包含 CO<10 和 CO<6 两行。但完整标题已经说明，这张表报告的是 sensitivity analysis。

**二、C008 在既有记录中如何演变**

| 阶段 | 发生的事情 |
|---|---|
| Statistical pass 1 | `F-ST1-008` 将表格中的 primary 区块解释为 outcome status 差异，引用 Route A, category 5。 |
| 初始 screening | 决定 `INCLUDE / MEETS_THRESHOLD`，注册为 C008。 |
| Evidence recheck | 扩展核查至正文两条 CO<6 行，并加入 `S_W`；记录为 `reproduced_after_transcription_correction`。 |
| Statistical pass 2 | 保留既有 C008，没有重复注册。 |
| Quality audit | 标记 `QUESTIONED`：表格分组存在，但正式 outcome status 改变未被建立。 |
| 最终报告 | 保留 C008、原始 screening provenance 及上述 audit concern，继续等待人工 adjudication。 |

对应记录：[初始 finding](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/checkers/statistical_pass_1.md:140>)、[screening](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/screening/inclusion_screen.md:37>)、[recheck](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md:241>)、[quality audit](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/quality/evidence_quality_audit.md:357>)、[最终报告](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/final_report_1_6_2.md:574>)。

当前记录字段为：

- Review domain：`protocol_report`
- Relationship type：`P_R`
- All relationships：`P_R, S_C, S_W`
- Evidence state：`reproduced_after_transcription_correction`
- Inclusion audit：`QUESTIONED`

这里的 evidence state 不能单独理解为“outcome status 改变已经成立”。Recheck 明确说明，它确认的是表格分组，并纠正了正文 p.6 的位置描述、加入 `S_W`；它也明确没有推断 sensitivity analysis 实际被提升为 prespecified primary endpoint。

**三、我的独立探索与判断依据**

我直接核查了 SAP、正文 Methods、Results、Table 2，以及 eTable 9 的完整标题和分组；另有一名 reviewer 在不读取既有结论的情况下独立检查源文。

本次判断主要依据以下区别：

1. **表格区块可以按 outcome 分组，而不是给每一行指定正式 hierarchy。**  
   [Table 2，正文 PDF p.6](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=6>)的单数 “Primary outcome” 区块不仅包含 CO<6，还包含 CO<10 的 ITT／PP，以及 self-reported-only 分析。这支持“同一 primary outcome 的不同分析放在一起”的理解。

2. **正式定义与 Methods 没有显示 primary threshold 从10改为6。**  
   SAP 使用 CO<10；正文 outcome definition 也使用 CO<10；CO<6 则明确被称为 post hoc sensitivity analysis。没有找到声明其成为新增 prespecified primary endpoint 的句子。

3. **Route A5 的前提需要先被重现。**  
   “实际发生 planned outcome status 改变”可以触发该类别，但不能仅凭区块标题先假定状态改变，再用 always-register 规则排除其他解释。本次重现了表格位置，未重现其被提升为正式 primary endpoint 的命题。

4. **Route B 的 context 要求也未得到支持。**  
   Methods、Results 及 eTable 9 标题共同给出了直接解释。独立 source-only reviewer 对“正式状态提升”这一命题给出的 reason code 是 `NOT_REPRODUCED`；这只是本次独立核查意见，没有替换既有 screening row，也没有删除 C008。

既有记录中其实已经存在分歧：[cross-source checker 的 excluded observation](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/checkers/cross_source_consistency.md:220>)认为，该现象属于 `TERMINOLOGY_OR_WORDING`，因为上下文已经说明这些是同一 primary endpoint 的 sensitivity analyses。后来的 `QUESTIONED` audit 与这一理解一致。

最终报告同时保留了最初的 Route A5 论据和后来的 audit challenge，因此不能只读取其 “Qualifying route” 字段，就认为纳入前提已获一致支持。

**四、本次发现的源文与审查记录转录差异**

正文 Table 2 的 CO<6 PP 行实际印为：

| 项目 | 原始 PDF |
|---|---|
| mHealth | 264/667 |
| Usual care | **38/318** |
| Usual-care percentage | **11.9（95% CI，8.6–16.1）** |

我和独立 reviewer 均直接读取为 **38/318**，native extraction 也一致；可查看[本次源文局部渲染](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c008_20261021/main_p6_pp_cell.png>)。

既有 recheck、audit 及最终报告却写成 **39/318**，audit 还据此进行了辅助计算。该计算并不对应实际源单元格。源文的：

\[
100\times38/318=11.9497\%
\]

与其显示的11.9%相符。

**这项差异发生在审查记录的转录中，不能据此认定文章存在相应 participant-count discrepancy。**它也不支持 CO<6 的 outcome status 发生改变。

**五、可能的 downstream impact**

C008 当前属于 `protocol_report`，并非你条件中指定的 `statistical_results`。其潜在影响主要涉及 extraction metadata：

- 若仅依据区块标题，extractor 可能把 CO<6 的 RR 3.7 当成正式 primary result，而原文明确报告的 CO<10 primary ITT RR 是3.0［95% CI，2.0–4.9］。
- 不同 thresholds、ITT／PP 及 excluding-deaths analyses 若被混用，可能导致结果选择或重复提取问题；供应材料没有显示这种传播实际发生。
- 表格分组本身没有建立 RR、95% CI、statistical significance 或研究结论需要改变。
- 另外，若直接复制既有审查报告的39/318，会把与源文不一致的 count 继续传递。该单元格应以原始 PDF 的38/318为依据。

新增文件全部位于指定目录，原始材料及既有记录未修改；三个源 PDF 的 SHA-256 检查均通过。完整依据见[独立源文核查](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c008_20261021/independent_source_check.md>)及[既有记录对照](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c008_20261021/coordinator_comparison.md>)。

---

### 12. User

continue on C009

---

### 13. Assistant — progress update

我会按同样要求复查 C009：先核查原始材料及上下文，再对照既有记录，用中文说明处理经过、关键英文原句及适用的下游影响。新增文件仍仅写入 `review_records/re_explorations/`。

---

### 14. Assistant — progress update

C009 涉及 protocol 的 missing-at-random 表述，与 SAP／论文把 missing primary outcomes 记为未戒烟之间的对应关系。我会重点核查这两种说明是否针对同一分析，或是否由临近的 health-economic 内容、不同 analysis sets 或版本更新作了解释。如需补充页面渲染，继续使用 CPU；GPU OCR 仅在你提出并同意所用引擎后使用。

---

### 15. Assistant — progress update

源文已确认：SAP 与论文对 missing primary outcomes 的处理一致，均将其记为未戒烟；protocol 则在独立的 “Statistical analysis” 小节中写明 missing-at-random architecture。人数也能对上：两组分别有53和42人未提供 primary outcome，primary analysis 保留720和360人的 denominators；剔除这些人后为667和318。因此，C009 的核心是分析说明之间如何对应，并非人数不相符。

---

### 16. Assistant — progress update

需要说明一项执行偏差：独立复查子任务把10张新渲染页写到了旧的 `preprocessing/` 目录，违反了你指定的写入范围。抱歉，我已要求将这10张本次新建文件移入允许目录，并检查旧记录是否保持不变；后续说明会如实保留这项经过。

---

### 17. Assistant — answer

**C009 在既有审查中被保留：两个 findings 合并为一个 candidate，最终为 `reproduced`、Inclusion audit `CONFIRMED`，仍是 `Pending Human Adjudication`。**

我的独立复查支持其较窄的表述：**protocol 的 missing-at-random（MAR）说明，与 SAP／论文明确采用的 missing-as-not-abstinent 规则，缺少清楚的适用范围及对应说明。**但不能将其扩大为“MAR 与这种处理在数学上必然不相容”，也不能据此推断 bias 或研究结论改变。

**一、原始材料的关键句及位置**

**① Protocol 写明 missing-at-random architecture。**

位置：[Supplement 1，PDF p.28](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=28>)，§11.2.2 “Statistical analysis”，行760–762；同样文字重复于 [PDF p.66](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=66>)，§28.2.2，行2012–2014：

> “Outcomes will be primarily analysed in a missing-at-random architecture by fitting generalised linear mixed models using a log link and assuming an underlying Poisson distribution with clusters treated as a random effect.”

中文：Outcomes 将主要在 missing-at-random architecture 下，通过 generalised linear mixed models 进行分析，采用 log link，假定基础分布为 Poisson distribution，并将 clusters 作为 random effect。

这里需要注意：原句泛称 **“Outcomes”**，没有直接限定为 primary abstinence outcome，也没有明确限定为经济学 outcomes。这正是需要澄清的范围问题。

**② SAP 明确把 dropout／incomplete data 记为继续吸烟。**

位置：[Supplement 1，PDF p.91](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=91>)，SAP 文内 p.14，§30 “Primary outcome Analysis”，行2890–2892：

> “The primary outcome analysis will utilize an intention-to-treat (ITT) method. Patients who drop out or have incomplete data will be regarded as continuing smokers in line with the Russell Standard methodology (West et al., 2005).”

中文：primary outcome analysis 将采用 intention-to-treat（ITT）method。退出或数据不完整的参与者，将按照 Russell Standard methodology 记为继续吸烟。

SAP 还单独规定了排除 missing outcomes 的分析。位置：[PDF p.92](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=92>)，§37 “Analysis excluding missing data”，行2930–2932：

> “The primary logistic regression will be repeated for patients with available outcome data only, i.e. excluding patients for whom primary outcome data was missing.”

中文：将仅对有 available outcome data 的参与者重复 primary logistic regression，即排除 missing primary outcome data 的参与者。

**③ 论文的处理说明与 SAP 一致。**

位置：[正文，PDF p.3](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=3>)，文内 p.338，右栏 “Statistical Analysis”：

> “Consistent with standard practice in smoking cessation trials, missing primary outcome data were treated as a negative outcome (ie, not abstinent).”

中文：按照文中所述的戒烟试验常规做法，missing primary outcome data 被记为 negative outcome，即未戒烟。

紧接着写道：

> “The intervention effect estimates were assessed through both intention-to-treat and complete case analyses (those with missing primary outcome data were discarded).”

中文：intervention effect estimates 分别通过 intention-to-treat 和 complete case analyses 评估；complete case analyses 剔除了 missing primary outcome data 的参与者。

因此，**论文清楚说明了报告采用的处理规则；尚待解释的是 protocol 的 MAR 说明与这些分析如何对应。**

**二、独立核对人数：没有发现 count discrepancy**

我直接核查了 [Figure 1，正文 PDF p.4](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=4>)和 [Table 2，PDF p.6](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=6>)：

| 项目 | mHealth | Usual care |
|---|---:|---:|
| Randomized／primary analysis denominator | 720 | 360 |
| 死亡 | 25 | 27 |
| 无法联系 | 18 | 9 |
| 退出 | 10 | 6 |
| 未提供 primary outcome 合计 | **53** | **42** |
| 剔除上述参与者后的 denominator | **667** | **318** |
| CO<10 ITT 戒烟人数 | 300 | 55 |

对应关系完全吻合：

- \(25+18+10=53\)，\(27+9+6=42\)；
- \(720-53=667\)，\(360-42=318\)；
- \(53+42=95\)，占1080人的8.796%，与正文8.8%一致。

Primary ITT 结果是300/720 versus 55/360，报告 RR 3.0［95% CI，2.0–4.9］。Available-outcome 行保留相同的300和55作为 numerators，denominators 为667和318。

这些数字支持文中描述的两种处理方式；**C009 并非由人数不相符产生。**

**三、C009 在既有记录中经历了什么**

| 阶段 | 记录中的处理 |
|---|---|
| Cross-source review | `F-XS-002` 提出 protocol MAR 与 SAP／report negative assignment 的对应问题。 |
| Statistical pass 1 | `F-ST1-004` 独立提出同一问题，对应 relationship `S089`。 |
| Inclusion screening | 两条 findings 均为 `INCLUDE / MEETS_THRESHOLD`，合并为 C009，采用 **Route B**。 |
| Evidence recheck | 确认原句、位置及人数关系，记录为 `reproduced`。 |
| Statistical pass 2 | 保留 C009，没有重复注册；没有推算另一套 efficacy estimate 或 bias。 |
| Quality audit／最终报告 | Inclusion audit 为 `CONFIRMED`，继续保留经济学范围和 SAP supersession 等解释。 |

对应记录：[screening](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/screening/inclusion_screen.md:18>)、[recheck](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md:273>)、[statistical pass 2](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/checkers/statistical_pass_2.md:323>)、[quality audit](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/quality/evidence_quality_audit.md:397>)、[最终报告](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/final_report_1_6_2.md:632>)。

最终分类为：

- Review domain：`protocol_report`
- Relationship type：`P_R`
- All relationships：`P_R, P_P`
- Evidence state：`reproduced`
- Inclusion audit：`CONFIRMED`

其中，protocol versus report 构成 `P_R`，protocol versus SAP 构成 `P_P`；按 precedence 选择 `P_R`。SAP 与论文在此处相互一致，没有额外的 `S_C` 或 `S_W` conflict。

`CONFIRMED` 是 inclusion audit 的记录，人工 adjudication 尚未完成。

**四、独立探索后，需要保留哪些限定**

我与另一名不读取既有审查结论的 reviewer 分别核查了源文，得到以下判断：

1. **经济学上下文确实相关，但不能直接限定 MAR 那一段。**  
   前面的段落讨论 costs、QALYs、multiple imputation 和 complete case analysis。然而，[PDF pp.27–28](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=27>)及[pp.65–66](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=65>)显示，“Statistical analysis”是与“Cost-effectiveness analysis”并列的小节。其 Outcomes 句子没有明确写成仅适用于 costs／QALYs，因此经济学邻接关系提供了一种解释，但没有完全建立适用范围。

2. **MAR 与 negative assignment 属于不同概念。**  
   MAR 描述 missingness mechanism／framework；把 missing abstinence outcome 记为未戒烟，是 operational analysis rule。两者可能用于不同 outcomes、不同 analysis sets 或不同 estimands，也可能分别涉及 outcomes 与 covariates。仅凭名称，不能证明它们普遍互斥。

3. **已报告 complete case analysis，并不能自动完成对应。**  
   Complete case analysis 的存在不等于已经识别出 protocol 所指的 MAR-based analysis。材料仍缺少明确说明：MAR 那句话究竟指哪一个分析，以及其 primary／sensitivity 地位。

4. **SAP 可能取代较概括的 protocol 说明，但版本对应没有被明确建立。**  
   [PDF p.77 的变更说明](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=77>)没有列出这项 missing-outcome 变更。文件在 bundle 中的先后位置也不能单独证明 supersession。这里不能进一步推断修改时间、是否接触 outcome data，或作者未披露某项变更。

因此，本次重现的是**计划说明的范围及其与报告分析之间尚未明确对应**，支持保留为待人工澄清的 reporting issue；证据没有建立实际模型必然不相容或结果受到某一方向的 bias。

**五、可能的 downstream impact**

C009 的 Review domain 是 `protocol_report`，并非你条件中指定的 `statistical_results`。不过，它可能影响后续提取的分析说明：

- Extractor 可能依据 protocol 将 primary RR 标记为 MAR-based handling，或依据论文标记为 missing-as-not-abstinent。论文明确支持后一个描述，计划与报告之间的对应仍需说明。
- ITT 的720／360与 available-outcome 的667／318，应分别与对应结果提取；混用可能改变所选 analysis set。
- 供应材料没有给出一套明确标识的替代 MAR-based result，无法量化更换处理规则对 RR、95% CI、meta-analysis weight 或结论的影响。
- 不能仅凭这些人数断言 missing-as-smoking 必然“conservative”，也不能推断 bias direction。

完整依据保存在[独立源文核查](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c009_20261021/independent_source_check.md>)及[既有记录对照](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c009_20261021/coordinator_comparison.md>)。源 PDF 与既有 reusable assets 的 hash 检查均通过。

本次有一项已纠正的执行偏差：子任务曾把10张新渲染页暂存到旧 `preprocessing/` 目录，现已全部移入允许目录，旧目录不再保留这些新增文件。原始文档和既有审查记录未被改写；该经过已如实记入复查记录。

---

### 18. User

continur on C010

---

### 19. Assistant — progress update

我会继续按同样要求复查 C010：先独立核查原始材料及上下文，再与既有记录对照，用中文说明处理经过、英文原句及适用的下游影响。所有新增文件将仅写入 `review_records/re_explorations/`。

---

### 20. Assistant — progress update

C010 指向 SAP 中计划的 male／female subgroup analyses 是否在结果中报告。我会区分 baseline sex counts、模型中对 sex 的 adjustment，以及分别报告 male／female treatment effects；这三者不能自动互相替代。复查优先使用已有页面图像，如需新渲染将使用 CPU。

---

### 21. Assistant — progress update

源文已确认：SAP 明确列出 gender（male vs. female），要求各 subgroup 报告 RR／95% CI，并说明应披露无法提供的 confidence intervals。完整 eTable 8 列出年龄、教育、职业、吸烟年限和阅读短信能力，没有 male／female 行。正文承认女性人数较少，但尚未找到说明因此未估计该计划分析的文字。

---

### 22. Assistant — answer

**C010 在既有审查中被保留：两个 findings 合并为一个 candidate，最终为 `reproduced`、Inclusion audit `CONFIRMED`，仍是 `Pending Human Adjudication`。**

我的独立复查重现了其核心观察：**SAP 明确计划对 primary outcome 进行 male／female subgroup analyses，但供应的正文与结果补充材料中，没有找到对应的 treatment RR／95% CI，也没有明确解释为何未报告。**这并不能证明分析从未进行，也不能推断男性与女性的 treatment effects 不同。

**一、原始材料的关键句及位置**

**① SAP 明确计划检查 primary treatment effect 在不同 subgroups 中的稳定性。**

位置：[Supplement 1，PDF p.92](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=92>)，SAP 文内 p.15，§38 “Sub-group Analyses”，行2937–2938：

> “We will perform sensitivity analyses to evaluate how stable the primary treatment effect remains across important subgroups.”

中文：将进行 sensitivity analyses，评估 primary treatment effect 在重要 subgroups 中的稳定性。

随后跨页列出的因素包括年龄、教育、职业、吸烟年限，以及明确的：

> “gender (male vs. female)”

中文：性别，male versus female。

该项位于 [PDF p.93](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=93>)，SAP 文内 p.16，行2942。因此，这不是根据人口构成自行提出的 subgroup analysis，而是供应 SAP 中明确列出的分析。

**② SAP 规定各 subgroup 应有自己的 model、RR 和95% CI。**

同页，行2943–2946：

> “Each subgroup will have its own mixed-effects model applied while accounting for clustering at site level through a random intercept. We will compute both the relative risk (RR) and the 95% confidence intervals (CIs) for smoking cessation.”

中文：每个 subgroup 将分别应用 mixed-effects model，通过 random intercept 考虑 site-level clustering，并计算戒烟的 relative risk（RR）及95% confidence intervals（CIs）。

**③ SAP 也预见了 statistical power 有限或无法提供 CI 的情况。**

同页，行2948–2950：

> “The researchers will disclose any missing confidence intervals while analyzing subgroup results with caution due to limited statistical power alongside their exploratory analysis nature.”

中文：研究者将披露无法提供的 confidence intervals；考虑到 statistical power 有限及其 exploratory analysis 性质，将谨慎解释 subgroup results。

这句话很关键：人数较少可能解释分析困难，但 SAP 本身已经预期需要说明 missing CIs。

**④ 正文报告的 subgroup consistency 范围没有包括 male／female。**

位置：[正文，PDF p.5](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=5>)，文内 p.340，右栏 subgroup-results 段：

> “Subgroup analyses demonstrated that the treatment effect remained consistent across age, education, employment, ability to read Short Message Service messages, and smoking duration categories (eTable 8 in Supplement 2).”

中文：Subgroup analyses 显示，treatment effect 在年龄、教育、就业、阅读短信能力及吸烟年限这些 categories 中保持一致。

这里没有提到性别；这句话本身也没有声称 treatment effect 在男性与女性之间一致。

**二、独立比较计划与完整结果表**

我核查了 [eTable 8，Supplement 2，PDF p.12](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp2_prod_1768590553.09463.pdf#page=12>)的完整页面：

| SAP 中计划的 subgroup factor | eTable 8 的对应情况 |
|---|---|
| Age | 有 |
| Education | 有 |
| Occupation | 有 |
| Gender：male／female | **没有对应行** |
| Smoking duration | 有 |

eTable 8 另外报告了 Reading SMS，包含 Yes／No 两行。该因素的存在不能提供缺少的 male／female treatment contrasts。

[SAP，PDF p.99](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp1_prod_1768590553.08963.pdf#page=99>)还保留了 “Gender—Male／Female” 的空白 table shell。它佐证计划中有这一项，但属于 PLAN，不能把空白格理解为已经报告的结果或 nonestimability 说明。

独立 reviewer 还搜索了完整正文与结果补充材料中的 sex、gender、male／female、subgroup、estimability、amendment 等相关表述，未找到另一个对应结果位置或明确的取消／未估计说明。

**三、C010 在既有记录中经历了什么**

| 阶段 | 记录中的处理 |
|---|---|
| Cross-source review | `F-XS-004` 提出计划的 male／female subgroup results 未报告。 |
| Statistical pass 1 | `F-ST1-006` 独立提出同一问题，对应 relationship `S097`。 |
| Inclusion screening | 两条 findings 均为 `INCLUDE / MEETS_THRESHOLD`，合并为 C010，采用 **Route A, category 5**。 |
| Evidence recheck | 确认计划原句及完整报告中的缺失，保留 `reproduced`，没有分类修订。 |
| Statistical pass 2 | 保留 C010，没有重复注册。 |
| Quality audit／最终报告 | Inclusion audit 为 `CONFIRMED`，继续保留编号及解释限制。 |

对应记录：[screening](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/screening/inclusion_screen.md:20>)、[recheck](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md:305>)、[statistical pass 2](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/checkers/statistical_pass_2.md:331>)、[quality audit](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/review_1_6_2/quality/evidence_quality_audit.md:435>)、[最终报告](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.ai_paper_validation/final_report_1_6_2.md:692>)。

最终字段为：

- Review domain：`protocol_report`
- Relationship type／All relationships：`P_R`
- Evidence state：`reproduced`
- Inclusion audit：`CONFIRMED`
- 状态：`Pending Human Adjudication`

正文与结果补充材料在此处没有互相冲突，因此没有额外的 `S_C`。`CONFIRMED` 指 inclusion audit，人工 adjudication 尚未完成。

**四、我的独立判断为何支持这一较窄的 reporting issue**

**1. Sex adjustment 不能代替 sex-specific treatment effects。**

[正文 PDF p.3](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=3>)确实把 sex 列为 adjustment covariate。但“总体模型调整 sex”与“分别在男性、女性中估计 mHealth versus usual care 的 treatment RR”是不同的 quantitative relationships。前者没有提供后者。

**2. 补充材料中一个与 Male 有关的 RR，也不是所需结果。**

[eTable 7，Supplement 2，PDF pp.10–11](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/joi250093supp2_prod_1768590553.09463.pdf#page=10>)列出 cluster characteristics，其中 “Male, n(%)” 对应的 association RR 为0.83［95% CI，0.34–2.02］。

它不是男性和女性各自的 intervention contrasts，不能用来填补计划的两个 subgroup treatment results。

**3. 女性人数少是实际观察，无法估计模型则仍是可能解释。**

[Table 1，正文 PDF p.5](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=5>)直接报告：

| Baseline sex | mHealth | Usual care |
|---|---:|---:|
| Male | 698 | 345 |
| Female | 22 | 15 |

女性共37人。[正文 PDF p.8，Limitations](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/jama_zahid_2025_oi_250093_1768590553.08463.pdf#page=8>)也明确承认参与者几乎全是男性。

但这些是 baseline composition，不能确定 female abstinence events、模型能否估计或是否发生 convergence difficulty。原文没有把男性占比高明确作为未报告计划分析的原因。

**4. 这里涉及 primary outcome 的 exploratory／sensitivity analyses。**

SAP 并没有因此设立两个新的 co-primary endpoints。它计划检查 primary treatment effect 在不同 subgroups 中的稳定性，并说明采用 RR／CI 的 qualitative comparison。本次没有据此追加“缺少 interaction P value”的要求。

**5. “未报告”仍需与“未进行”区分。**

分析可能未能估计、已经进行但未列入报告，或经 amendment 移除；本次材料没有确定是哪一种。供应 SAP 的文字也不能单独建立其在接触 outcome data 之前锁定的时间。

因此，本次支持的是：**明确写入 SAP 的 subgroup analysis，在供应报告中缺少对应结果或解释。**没有推断原因、意图或缺失结果的方向。

**五、可能的 downstream impact**

C010 当前属于 `protocol_report`，并非你条件中指定的 `statistical_results`。其潜在影响主要是可提取证据的范围：

- Evidence summary 若写成“所有计划的 subgroup analyses 均已报告”，会超出供应材料支持的范围。
- 无法提取 male／female-specific intervention RR／95% CI；缺失不代表两组没有差异，也不代表任一组无效。
- eTable 7 的0.83或 eTable 8 的 All RR，不能作为 male／female-specific intervention estimate。样本以男性为主，也不使 pooled result 自动成为 male-specific result。
- 没有 sex-specific outcome counts 或 model outputs，无法量化对总体 RR、95% CI、meta-analysis weight 或临床结论的影响。

完整依据见[独立源文核查](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c010_20261021/independent_source_check.md>)及[既有记录对照](</home/bulun-debian/ai-paper-val/2025/jama.2025.20765/review_records/re_explorations/c010_20261021/coordinator_comparison.md>)。本次所有新增文件均位于允许目录；原始材料和既有审查记录未改写，源文件及 reusable assets 的 hash 检查均通过。

---

### 23. User

save the current conversation into a markdown file under the ./review_records/. Name the markdown file contains "C007-C013" (although it was not finished, I will finish the markdown later)

---

### 24. Assistant — progress update

我会将当前可见对话按顺序保存为 Markdown，文件名包含 `C007-C013`，并注明目前已讨论到 C010，供你后续补充。

---

## C011 — To be continued

<!-- Add the C011 conversation here. -->

## C012 — To be continued

<!-- Add the C012 conversation here. -->

## C013 — To be continued

<!-- Add the C013 conversation here. -->

## Appendix — Initial user-supplied workspace context

Historical context reproduced verbatim; this appendix is part of the conversation record.

~~~~~text
# AGENTS.md instructions for /home/bulun-debian/ai-paper-val/2025/jama.2025.20765

<INSTRUCTIONS>
# Quantitative Quality-Control Review 1.6.2 — Reuse Existing Evidence Assets

The current project root is exactly one paper package. The package may contain earlier
`.ai_paper_validation/` records. Workflow 1.6.2 performs candidate discovery from the beginning, while
reusing all usable existing OCR, native text, layout text, table extraction,
workbook extraction, rendered pages, and document maps. Reuse is an optimization, not a coverage
boundary: every direct-source unit that lacks usable reusable extraction must be freshly inspected and
mapped from the supplied source. Every finding passes an independent inclusion screen under
`QUALITY_CONTROL_SCOPE.md` before it can become a candidate, and every candidate is assigned one of
four review domains.

Use English only in prompts, generated artifacts, logs, and reports. Preserve every supplied source
and every pre-existing audit artifact. Write new work only to:

- `.ai_paper_validation/review_1_6_2/`
- `.ai_paper_validation/final_report_1_6_2.md`
- `.ai_paper_validation/final_report_1_6_2.html`

## Agent-first execution

Start immediately and operate autonomously. The coordinator plans coverage, delegates bounded and
disjoint evidence scopes to specialist agents, merges their durable artifacts, and verifies coverage.
Python is auxiliary only. Do not use Python to orchestrate the scientific review, select or classify
candidates, or replace agent reasoning. Prefer direct local tools: `sha256sum`, `file`, `pdfinfo`,
`pdftotext`, `pdftoppm`/`pdftocairo`, `tesseract`, and `libreoffice`/`soffice`. The only permitted
Python helpers are those in `workflow_1_6_2/scripts/`: the optional Office structure extractor, the
tooling bootstrap and PDF/OCR/hash fallback helper described below, the report renderer, and the final
validator. Do not write other Python for extraction or OCR.

## Local tools and the temporary fallback environment

The review runs on a local machine (Linux, macOS, or Windows) where direct tools may be missing.
Before source inventory, probe the machine and record the result in
`.ai_paper_validation/review_1_6_2/tooling_record.md`:

```bash
python3 workflow_1_6_2/scripts/pdf_tools.py probe
```

If PDF information, text, or page rendering is unavailable as a direct tool, create the temporary
package-local fallback environment; add `--ocr` only when OCR may be needed and `tesseract` is absent:

```bash
python3 workflow_1_6_2/scripts/bootstrap_tooling.py create
```

The environment is created only under `.ai_paper_validation/review_1_6_2/tooling/`, with pinned
packages and a local package cache; never install into the global Python environment. Then use the
fallback helper with that environment's interpreter, and only for capabilities the probe recorded as
missing:

```bash
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py info "source.pdf"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/native-N.txt"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/layout-N.txt" --layout
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py render "source.pdf" --page N ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py ocr ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png" ".ai_paper_validation/review_1_6_2/preprocessing/ocr-N.txt"
python3 workflow_1_6_2/scripts/pdf_tools.py sha256 "source.pdf"
```

On Windows the interpreter is `.ai_paper_validation\review_1_6_2\tooling\venv\Scripts\python.exe`.
Every specialist uses the tooling recorded in `tooling_record.md`. Record the engine with every
derivative it produces. If installation fails, for example because the sandbox blocks network access,
record `INSTALL_FAILED`, continue with reusable assets and the tools that are available, inspect
rendered or reusable page images visually where text is unusable, and list every affected unit as a
limitation. A missing tool never permits omitting a source unit. After rendering HTML and before the
final validation, remove the environment with `python3 workflow_1_6_2/scripts/bootstrap_tooling.py
remove` and record the removal.

Use artifact-first handoffs. Every specialist writes complete English output to one unique assigned
path and returns only a compact status, exact scope, counts, limitations, and artifact path. Never let
two agents write the same artifact concurrently. Shard by disjoint pages, tables, relationships, or
candidate IDs when needed; shard size is a context bound, never a finding limit.

Do not put provider credentials or provider selection in the package-root `.codex/config.toml`.
The direct interactive session requires the ten bundled `.codex/agents/` role presets and verifies
each one before scientific work. Preserve unrelated package `.codex` controls when copying those
files. Validation does not rewrite `.codex/`.

## Run model selection

The default run model is `gpt-6.1-sol`, and every role uses one run model; roles differ only in
reasoning effort. Wherever these instructions, the presets, or the examples name `gpt-6.1-sol`, read
it as the run model. If `gpt-6.1-sol` is rejected or unavailable at preflight, or the user wants a
different model (for example a later release), stop before scientific work and ask the user which
exact model ID to use. Never choose a substitute model yourself. Once the user names it, set that ID
as `model` in `.codex/config.toml` and in all ten `.codex/agents/qc162-*.toml` presets (or confirm the
user has done so), and record `Run model: <ID>` with `Run model source: USER_SELECTED` in
`routing_preflight.md`; otherwise record `Run model: gpt-6.1-sol` with `Run model source: DEFAULT`.
Use an exact model ID, never a moving alias such as `~openai/gpt-latest`, so that repeated reviews
run under the same recorded conditions.

## CPU by default

Rendering and OCR run on the CPU by default. Before the first rendering or OCR step, tell the user in
the session that processing is running on the CPU and that GPU OCR can be used if they ask for it.
Use a GPU only after the user explicitly requests it, with a GPU-capable OCR engine the user approves;
record the device in `tooling_record.md` (`Compute device: CPU` or `Compute device: GPU_USER_REQUESTED`)
and the engine with every derivative.

## Model routing contract

Start from the package root with `codex --approve-for-me`, then send `Read START_PROMPT.md completely
and execute Workflow 1.6.2 now.` as the first request. The current Codex session supplies the provider
and authentication; do not configure or change a provider; the project config fixes the coordinator at the run model/`high` and the
ten named presets fix every specialist model/effort pair. Every role uses the run model (default
`gpt-6.1-sol`); roles differ only in reasoning effort. Do not use `~openai/gpt-latest`, another moving alias, a shell launcher, or
`codex exec` fallback.

Before scientific work, create `routing_preflight.md` and require it to report `PASS`, the run model and its source, coordinator
`gpt-6.1-sol`/`high`, ordinary specialists `gpt-6.1-sol`/`medium`, statistical specialists
`gpt-6.1-sol`/`high`, screening, recheck and audit specialists `gpt-6.1-sol`/`high`, `Coordinator
inference: PASS`, execution mode `INTERACTIVE_CLI`, `Provider: CURRENT_SESSION`, and all
ten named agent presets verified against their required pairs.

Every mandatory specialist stage uses a fresh agent and a distinct runtime ID. Use the named custom
agent preset when available. Otherwise use a fresh default agent, pass the exact fixed model and
reasoning effort for that role, and include the role contract in the spawn prompt. Never reuse an
agent for another mandatory stage, promote an agent with follow-up, omit a fallback model override, or
change the fixed reasoning effort of a role. Record the exact model ID in the execution manifest.

## Read before reviewing

Read completely:

- `QUALITY_CONTROL_SCOPE.md`
- `PERFORMANCE_PROFILE.md`
- `workflow_1_6_2/review_contract.md`
- `workflow_1_6_2/report_spec.md`
- `workflow_1_6_2/settings.toml`

Do not read an old candidate set, review queue, verifier disposition, critic decision, endetail
section, screening log, classification record, or final report as a scientific input or candidate
source. Preserve
those records unchanged, but build discovery and classification from source-linked reusable assets
plus mandatory direct-source inspection of every uncovered unit.

## Required workflow

1. Verify `routing_preflight.md` first, asking the user for a model if the default is unavailable.
   Probe local tools, tell the user that rendering and OCR run on the CPU unless they request a GPU,
   create the fallback environment if needed, and write `tooling_record.md`. Record the UTC start time, then inventory every direct source, its complete stable unit count, and
   SHA-256 in `.ai_paper_validation/review_1_6_2/source_hashes_before.sha256`. Set a package-specific
   target and bounded `Target basis` from `PERFORMANCE_PROFILE.md`; do not infer either from SAP length
   or page count alone. Initialize every required field in `run_state.md`. Initialize
   `agent_execution_manifest.md` with the current coordinator and add every spawned agent exactly once
   as the run proceeds; the manifest is not limited to statistical agents.
2. Use a fresh `qc162_reuse_asset_curator` agent to inventory and hash every reused OCR/text/table/page/document-map
   artifact in `reused_artifact_hashes_before.sha256` (or, when the package has none, write the single
   line `# NO_REUSABLE_ASSETS` there and count every unit as fresh-required), assess its coverage and
   fitness, and write the
   source and evidence-asset inventories. In `source_coverage.md`, record one row per direct source with
   total, reusable, fresh-required, and mapped unit counts, and record each direct source's document
   role (`REPORT` or `PLAN`) by content in `source_inventory.md`. Do not modify reused artifacts.
3. Compare reusable coverage against every direct-source unit. Assign every uncovered page, sheet,
   record group, paragraph group, and table group to fresh direct-source extraction and mapping. The
   reusable and fresh-required unit counts must partition the total, and mapped units must equal the
   total before completion. A reusable-derivative gap may remain a limitation; a scientific-coverage
   gap may not.
4. Create `coverage_manifest.md` before scientific mapping. Record every disjoint source/evidence unit
   and stage assignment. Each table row contains exactly one plain relative artifact path; put every
   shard part on its own row.
5. Run fresh, distinct `qc162_main_quantitative_mapper` and `qc162_support_quantitative_mapper` agents in parallel over the
   disjoint union of reusable-backed and fresh-required units. Reconstruct every result-relevant
   numeric and statistical relationship.
6. Run numeric and cross-source review in two distinct fresh `gpt-6.1-sol`/`medium` agents. Independently spawn a new
   `gpt-6.1-sol`/`high` agent for statistical pass 1; do not reuse a mapper agent or use follow-up to
   request a reasoning-effort change. Each checker applies the inclusion threshold and the
   screened-out catalogue of `QUALITY_CONTROL_SCOPE.md` to its own observations, emits a finding ID
   (`F-NUM-001`, `F-XS-001`, `F-ST1-001`, ...) only for an observation it judges to meet the
   threshold, consolidates a repeated pattern into one finding, and lists its other observations in a
   compact `Excluded observations` table with one reason code each. Every finding records the compared
   locations, the document role of each, the proposed review domain, the affected result or extracted
   value, and why context does not resolve it. Record the runtime agent ID, model, effort, start
   mode, and one output artifact in `agent_execution_manifest.md`.
7. Run a fresh `qc162_inclusion_screener`/`high` agent over every finding from the three checkers. It
   rereads each cited source location, applies the inclusion threshold independently, consolidates
   findings that describe the same issue or pattern, and writes `screening/inclusion_screen.md` with
   one row per finding: `INCLUDE` or `SCREENED_OUT` with exactly one reason code. It never sets a
   target number and never compares with other papers.
8. Assign `C001`, `C002`, ... only to the included issues, in source order, and write
   `candidate_ledger.md`. Preserve the finding IDs, checker provenance, and every affected location.
   Assign each candidate its review domain, a provisional relationship type, and all relationships
   under `QUALITY_CONTROL_SCOPE.md`, and write the classification table required by the review
   contract. Write the candidate ID back into each `INCLUDE` row of the screening log.
9. Run a fresh `qc162_evidence_rechecker`/`high` agent over every stable ID against the exact source page or truthful Office
   location. Existing OCR/text is a locator and transcription aid, not final authority. The rechecker
   confirms or corrects each document-role assignment, relationship type, and review domain from
   content, and assigns the evidence state.
10. Spawn a different new `gpt-6.1-sol`/`high` agent for statistical pass 2 over every statistical
   relationship, the complete ledger, the screening log, and all recheck facts. Record its distinct
   runtime ID in `agent_execution_manifest.md`. It rereads every checker `Excluded observations` row
   against the route A (always-register) categories and the display-precision rule of `QUALITY_CONTROL_SCOPE.md` and
   emits a finding for any row that belongs there. If it emits new findings (`F-ST2-001`, ...), screen
   them with a different fresh `qc162_inclusion_screener`/`high` agent recorded as stage
   `inclusion_screener_pass_2`, append included issues to the ledger without renumbering, classify
   them, then recheck every appended ID.
11. Run a fresh `qc162_quality_control_auditor`/`high` agent over every stable ID, every screening
   decision, every checker `Excluded observations` table, every coverage row, the complete
   `source_coverage.md`, the classification table, and the execution manifest. Audit whether each
   candidate meets the inclusion threshold and record `CONFIRMED` or `QUESTIONED` with a reason, audit
   screening decisions in both directions, and audit every relationship type, precedence decision,
   review domain, and evidence state. A wrongly screened-out finding that meets the threshold is
   appended as a new candidate and rechecked; an assigned candidate ID is never deleted or suppressed.
12. Run a fresh `qc162_report_generator`/`medium` agent to assemble the complete Markdown report. It must contain every
    candidate in the ledger with its classification fields, an inclusion screening summary, and a
    review-domain summary. If no candidate is found after complete coverage, produce a zero-candidate
    report that states the completed scope, the screening summary, and limitations. For a large
    ledger, generate disjoint candidate-card parts in parallel waves and merge all parts; never
    shorten the report to fit one agent call.
13. Immediately after Markdown assembly, finalize `run_state.md` and copy the exact performance fields
    into the report. Recompute source and reused-artifact hashes, render HTML once, remove the
    fallback environment if one was created, finalize `tooling_record.md`, and validate:

```bash
python3 workflow_1_6_2/scripts/render_report.py \
  .ai_paper_validation/final_report_1_6_2.md \
  .ai_paper_validation/final_report_1_6_2.html \
  --profile 1.6.2
python3 workflow_1_6_2/scripts/bootstrap_tooling.py remove
python3 workflow_1_6_2/scripts/validate_review.py --profile 1.6.2 --package .
```

Repair correctable validation failures until
`.ai_paper_validation/review_1_6_2/review_validation.json` reports `PASS`.
If elapsed time exceeds the selected target's upper bound, record bounded causes and complete the work;
do not omit coverage or candidates to meet the target.
If a repair requires another model call after `Finished UTC`, update the finish time, manifest, and
report timing fields before rendering and validation.

## Fixed scientific and communication boundaries

- Focus on counts and denominators, estimate and test logic, statistical method logic, and planned
  versus reported statistical design, as defined in `QUALITY_CONTROL_SCOPE.md`.
- Register only issues that meet the inclusion threshold. Screen out differences within the display-precision
  rule (relative discrepancy at most 0.05) and display-zero P values, notation and typographic slips, terminology and
  wording differences that a reader in the field resolves at once, model-based estimates compared with
  crude ratios, conditional observations, peripheral cross-document comparisons, and out-of-focus
  differences. A reproduced finding qualifies by route A (an always-register category of
  `QUALITY_CONTROL_SCOPE.md`, including every interval-versus-P-value or test conflict) or by route B
  (in focus, not resolved by context, and bearing on interpretation or extraction). When in doubt
  about wording, terminology, or a symbol, screen it out; when in doubt about a printed number,
  interval, P value, count, or planned-versus-reported element, register it.
- Keep cross-document and cross-location comparisons, tiered as in `QUALITY_CONTROL_SCOPE.md`: primary
  and key secondary results, misattributed results, quantity-changing labels, and planned-versus-
  reported analysis, endpoint, outcome-status, and intervention elements can qualify; copies of
  baseline descriptive values,
  per-time-point counts, pointers, sites, recruitment calendars, and other plan-internal details are
  peripheral unless they change a primary or key secondary result, an analysis-population size, or a
  planned decision rule.
- Register one candidate per issue; a repeated pattern is one candidate with all affected locations.
- There is no expected, typical, minimum, maximum, or target number of candidates.
- Do not perform a broad methodology, study-design, clinical, novelty, misconduct, or raw-data audit,
  and do not propose a preferred analysis.
- Use only supplied package evidence. Do not browse the web or use external literature.
- Never describe a candidate, a value, or the authors' work with the words error, mistake, defect,
  erroneous, wrong, or incorrect. Use candidate, reporting issue, inconsistency, discrepancy, unclear,
  or does not reconcile. Established statistical terms such as standard error keep their names.
- Assign every candidate one of the four review domains (`statistical_results`,
  `report_internal_inconsistency`, `protocol_report`, `plan_material`), consistent with its
  relationship type. These fields pre-fill human review and are not adjudications.
- Never assign `Major`, `Minor`, `Verified`, `Rejected`, `Uncertain`, severity, validity, acceptance,
  a suggested disposition, or a final correction, and never delete a candidate. Every candidate
  remains `Pending Human Adjudication`.
- Preserve 1.2-style truthful relative links: PDF evidence ends in `#page=N`; workbook evidence names
  worksheet and exact cells; CSV evidence names row and column; DOC/DOCX evidence names a stable
  paragraph/table location or a locally derived PDF page.
- The default target is a local CPU machine. Reuse existing OCR first. Use direct native/layout
  extraction for uncovered units, or the recorded fallback helper when a direct tool is missing, and
  targeted OCR only when text is unusable or visual confirmation requires it. Tell the user that
  processing runs on the CPU, and use a GPU only on the user's explicit request (see "CPU by
  default").

## Completion

Do not finish until every direct-source row has mapped units equal to total units; all coverage rows
are complete and contain one artifact path; routing preflight is `PASS`; every mandatory specialist
stage has a distinct fresh runtime agent with the required model and effort; both fresh
`gpt-6.1-sol`/`high` statistical agents cover every registered relationship; every actual agent
including the coordinator appears in the execution manifest; ledger/recheck/quality/report ID sets are
identical; every checker finding has exactly one screening decision and every included finding maps
to a candidate; every candidate has a complete classification that agrees between the ledger and the
report; `tooling_record.md` is complete and any fallback environment has been removed; every local
evidence link resolves; source and reused-artifact hashes are unchanged; standalone
HTML exists with embedded CSS and a table of contents; and the validator reports `PASS`.

</INSTRUCTIONS>

<environment_context>
  <cwd>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765</cwd>
  <shell>bash</shell>
  <current_date>2026-10-21</current_date>
  <timezone>America/Phoenix</timezone>
  <filesystem><workspace_roots><root>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765</root></workspace_roots><permission_profile type="managed"><file_system type="restricted"><entry access="read"><special>:root</special></entry><entry access="write"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765</path></entry><entry access="write"><special>:slash_tmp</special></entry><entry access="write"><special>:tmpdir</special></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.git</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.agents</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.codex</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.20765/.aws</path></entry></file_system></permission_profile></filesystem>
</environment_context>
~~~~~

